Phase 3 Relapsing Remitting Multiple Sclerosis Clinical Trials
3 recruitingPhase 3
What is a Phase 3 trial?
Phase 3 trials compare the new treatment against the current standard of care in large groups, often hundreds to thousands of participants. Successful Phase 3 results are typically required for regulatory approval.
Showing 1–3 of 3 trials
Recruiting
Phase 3
RItuximab Versus Ocrelizumab in Relapsing-remitting Multiple Sclerosis.
Multiple SclerosisRelapsing Remitting Multiple Sclerosis
Rennes University Hospital386 enrolled23 locationsNCT05758831
Recruiting
Phase 3
Best Available Therapy Versus Autologous Hematopoietic Stem Cell Transplant for Multiple Sclerosis (BEAT-MS)
Relapsing Multiple SclerosisRelapsing Remitting Multiple SclerosisSecondary Progressive Multiple Sclerosis
National Institute of Allergy and Infectious Diseases (NIAID)156 enrolled22 locationsNCT04047628
Recruiting
Phase 3
A Study to Compare Efficacy, Pharmacokinetics, Pharmacodynamics and Safety of CT-P53 and Ocrevus in Patients With Relapsing-remitting Multiple Sclerosis
Relapsing Remitting Multiple Sclerosis
Celltrion512 enrolled1 locationNCT05906992